{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T12:58:03Z","timestamp":1792155483238,"version":"4.4.0"},"reference-count":78,"publisher":"Informa UK Limited","issue":"2","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Biological Therapy"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1080\/14712598.2024.2445674","type":"journal-article","created":{"date-parts":[[2025,1,9]],"date-time":"2025-01-09T04:14:36Z","timestamp":1736396076000},"page":"149-159","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":3,"title":["Integrating gene therapy into the treatment paradigm for non-muscle invasive bladder cancer"],"prefix":"10.1080","volume":"25","author":[{"given":"Alexis R.","family":"Steinmetz","sequence":"first","affiliation":[{"name":"The University of Texas MD Anderson Cancer Center","place":["Houston, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Behzad","family":"Jazayeri","sequence":"additional","affiliation":[{"name":"Moffitt Cancer Center","place":["Tampa, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morgan","family":"Pierce","sequence":"additional","affiliation":[{"name":"The University of Texas MD Anderson Cancer Center","place":["Houston, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharada","family":"Mokkapati","sequence":"additional","affiliation":[{"name":"The University of Texas MD Anderson Cancer Center","place":["Houston, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"McConkey","sequence":"additional","affiliation":[{"name":"Johns Hopkins University","place":["Baltimore, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger","family":"Li","sequence":"additional","affiliation":[{"name":"Moffitt Cancer Center","place":["Tampa, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colin P.","family":"Dinney","sequence":"additional","affiliation":[{"name":"The University of Texas MD Anderson Cancer Center","place":["Houston, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2025,1,9]]},"reference":[{"key":"e_1_3_5_3_1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660"},{"key":"e_1_3_5_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2018.09.001"},{"key":"e_1_3_5_5_1","doi-asserted-by":"publisher","DOI":"10.1097\/JU.0000000000003846"},{"key":"e_1_3_5_6_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.57.6967"},{"key":"e_1_3_5_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2020.08.004"},{"issue":"1","key":"e_1_3_5_8_1","first-page":"13","article-title":"Pharmacologic therapies for non-muscle invasive bladder cancer: current and future treatments","volume":"4","author":"Goldberg IP","year":"2022","unstructured":"Goldberg IP, Lichtbroun B, Singer EA, et al. Pharmacologic therapies for non-muscle invasive bladder cancer: current and future treatments. Arch Pharmacol Ther. 2022;4(1):13\u201322.","journal-title":"Arch Pharmacol Ther"},{"key":"e_1_3_5_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2005.12.031"},{"key":"e_1_3_5_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2009.07.016"},{"key":"e_1_3_5_11_1","doi-asserted-by":"publisher","DOI":"10.3109\/02656736.2016.1142618"},{"key":"e_1_3_5_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2020.12.025"},{"key":"e_1_3_5_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2022.08.003"},{"key":"e_1_3_5_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2020.02.012"},{"key":"e_1_3_5_15_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.64.4070"},{"key":"e_1_3_5_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2013.10.030"},{"key":"e_1_3_5_17_1","unstructured":"Food and Drug Administration. Bcg-unresponsive nonmuscle invasive bladder cancer: developing drugs and biologics for treatment guidance for industry [internet]. 2018 [cited 2024 Jun 3]. Available from: https:\/\/www.fda.gov\/media\/101468\/download"},{"key":"e_1_3_5_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00147-9"},{"key":"e_1_3_5_19_1","unstructured":"Food and Drug Administration. FDA approves pembrolizumab for bcg-unresponsive high-risk non-muscle invasive bladder cancer [internet]. 2020 [cited 2024 Jun 3]. Available from: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-pembrolizumab-bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer"},{"key":"e_1_3_5_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30540-4"},{"key":"e_1_3_5_21_1","unstructured":"Food and Drug Administration. FDA D.I.S.C.O. Burst edition: FDA approval of adstiladrin (nadofaragene firadenovec-vncg) for patients with high-risk Bacillus Calmette-Gu\u00e9rin unresponsive non-muscle invasive bladder cancer with carcinoma in situ with or without papillary tumors [internet]. 2023 [cited Jun 6]. Available from: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-disco-burst-edition-fda-approval-adstiladrin-nadofaragene-firadenovec-vncg-patients-high-risk"},{"key":"e_1_3_5_22_1","doi-asserted-by":"publisher","DOI":"10.1056\/EVIDoa2200167"},{"key":"e_1_3_5_23_1","unstructured":"Food and Drug Administration. FDA approves nogapendekin alfa inbakicept-pmln for bcg-unresponsive non-muscle invasive bladder cancer [internet]. 2024 [cited 2024 Jun 6]. Available from: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-nogapendekin-alfa-inbakicept-pmln-bcg-unresponsive-non-muscle-invasive-bladder-cancer"},{"key":"e_1_3_5_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(05)64273-5"},{"key":"e_1_3_5_25_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.4_suppl.TPS715"},{"key":"e_1_3_5_26_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-020-00313-1"},{"key":"e_1_3_5_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0007-4551(20)30278-2"},{"key":"e_1_3_5_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(17)58737-6"},{"key":"e_1_3_5_29_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14133073"},{"key":"e_1_3_5_30_1","doi-asserted-by":"publisher","DOI":"10.1159\/000052375"},{"key":"e_1_3_5_31_1","doi-asserted-by":"publisher","DOI":"10.3390\/curroncol31020079"},{"key":"e_1_3_5_32_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.4_suppl.588"},{"key":"e_1_3_5_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2023.08.004"},{"key":"e_1_3_5_34_1","doi-asserted-by":"publisher","DOI":"10.4103\/0970-1591.166446"},{"key":"e_1_3_5_35_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2018.4657"},{"key":"e_1_3_5_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(17)37585-7"},{"key":"e_1_3_5_37_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.ju.0000168657.51551.49"},{"key":"e_1_3_5_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.euo.2022.05.005"},{"key":"e_1_3_5_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.euo.2023.06.011"},{"key":"e_1_3_5_40_1","doi-asserted-by":"publisher","DOI":"10.1097\/JU.0000000000003977"},{"key":"e_1_3_5_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.euf.2023.06.006"},{"key":"e_1_3_5_42_1","unstructured":"Study of ONCOFID-P-B (PACLITAXEL-HYALURONIC ACID; ClinicalTrials.Gov identifier NCT05024773) [Internet]. 2021 [cited 2024 Jun 3]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05024773?cond=NCT05024773&rank=1"},{"key":"e_1_3_5_43_1","unstructured":"A study of TAR-200 in combination with cetrelimab or TAR-200 alone versus intravesical Bacillus Calmette-Gu\u00e9rin (BCG) in participants with bcg-na\u00efve high-risk non-muscle invasive bladder cancer (HR-NMIBC) (SunRise-3; ClinicalTrials.Gov identifier NCT05714202) [Internet]. 2023 [cited 2024 Jun 6]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05714202"},{"key":"e_1_3_5_44_1","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2023-0271"},{"key":"e_1_3_5_45_1","unstructured":"Atezolizumab in treating patients with recurrent bcg-unresponsive non-muscle invasive bladder cancer (ClinicalTrials.Gov identifier NCT02844816]. 2016 [cited 2024 Jun 6]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT02844816?cond=Atezolizumab%20in%20Treating%20Patients%20With%20Recurrent%20BCG-Unresponsive%20Non-muscle%20Invasive%20Bladder%20Cancer.&rank=1"},{"key":"e_1_3_5_46_1","unstructured":"Food and Drug Administration. Long term follow-up after administration of human gene therapy products; guidance for industry [Internet]. 2020 [cited Aug 6]. Available from: https:\/\/www.fda.gov\/media\/113768\/download"},{"key":"e_1_3_5_47_1","unstructured":"European Medicines Agency CAT. Reflection paper on classification of advanced therapy medicinal products [Internet]. 2015 [cited Aug 6]. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/reflection-paper-classification-advanced-therapy-medicinal-products_en.pdf-0"},{"key":"e_1_3_5_48_1","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines2020149"},{"key":"e_1_3_5_49_1","doi-asserted-by":"publisher","DOI":"10.3390\/cimb45060307"},{"key":"e_1_3_5_50_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1260498"},{"key":"e_1_3_5_51_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.omto.2022.06.005"},{"key":"e_1_3_5_52_1","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19870201)59:3 <613::AID-CNCR2820591307>3.0.CO;2-3"},{"issue":"4","key":"e_1_3_5_53_1","first-page":"808","article-title":"Inhibition of basic fibroblast growth factor expression, angiogenesis, and growth of human bladder carcinoma in mice by systemic interferon-alpha administration","volume":"58","author":"Dinney CP","year":"1998","unstructured":"Dinney CP, Bielenberg DR, Perrotte P, et al. Inhibition of basic fibroblast growth factor expression, angiogenesis, and growth of human bladder carcinoma in mice by systemic interferon-alpha administration. Cancer Res. 1998 Feb 15;58(4):808\u2013814.","journal-title":"Cancer Res"},{"key":"e_1_3_5_54_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ucl.2019.09.011"},{"key":"e_1_3_5_55_1","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2019.1577125"},{"key":"e_1_3_5_56_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cytogfr.2007.06.007"},{"key":"e_1_3_5_57_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1078-1439(03)00077-2"},{"key":"e_1_3_5_58_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.gt.3301348"},{"issue":"10","key":"e_1_3_5_59_1","first-page":"2726","article-title":"Interferon-alpha-mediated down-regulation of angiogenesis-related genes and therapy of bladder cancer are dependent on optimization of biological dose and schedule","volume":"5","author":"Slaton JW","year":"1999","unstructured":"Slaton JW, Perrotte P, Inoue K, et al. Interferon-alpha-mediated down-regulation of angiogenesis-related genes and therapy of bladder cancer are dependent on optimization of biological dose and schedule. Clin Cancer Res. 1999 Oct;5(10):2726\u20132734.","journal-title":"Clin Cancer Res"},{"key":"e_1_3_5_60_1","doi-asserted-by":"publisher","DOI":"10.1038\/cgt.2011.26"},{"key":"e_1_3_5_61_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2013.03.030"},{"key":"e_1_3_5_62_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.72.3064"},{"key":"e_1_3_5_63_1","doi-asserted-by":"publisher","DOI":"10.1097\/JU.0000000000004020"},{"key":"e_1_3_5_64_1","unstructured":"Ferring. Ferring advances three studies in ADSTILADRIN (nadofaragene firadenovec-vncg) clinical trials program [Internet]. 2024 [cited 2024 Dec 5]. Available from: https:\/\/ferringusa.com\/?press=ferring-advances-three-studies-in-adstiladrin-nadofaragene-firadenovec-vncg-clinical-trial-program"},{"key":"e_1_3_5_65_1","unstructured":"CG Oncology. Cretostimogene grenadenorepvec clinical studies [Internet]. 2024 [cited 2024 Dec 3]. Available from: https:\/\/cgoncology.com\/pipeline"},{"key":"e_1_3_5_66_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3770"},{"key":"e_1_3_5_67_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature01850"},{"key":"e_1_3_5_68_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-05-1059"},{"key":"e_1_3_5_69_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-03324-9"},{"key":"e_1_3_5_70_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41585-021-00483-z"},{"key":"e_1_3_5_71_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2012.07.097"},{"key":"e_1_3_5_72_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2017.07.005"},{"key":"e_1_3_5_73_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.JU.0001015816.87470.c9.02"},{"key":"e_1_3_5_74_1","unstructured":"CG Oncology. Groundbreaking cretostimogene grenadenorepvec monotherapy data demonstrates sustained durable complete responses in high-risk bcg-unresponsive non-muscle invasive bladder cancer [Internet. 2024 [cited 2024 Dec 5]. Available from: https:\/\/ir.cgoncology.com\/news-releases\/news-release-details\/groundbreaking-cretostimogene-grenadenorepvec-monotherapy-data"},{"key":"e_1_3_5_75_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-03025-3"},{"key":"e_1_3_5_76_1","unstructured":"A study of adjuvant cretostimogene grenadenorepvec for treatment of intermediate risk NMIBC following TURBT (ClinicalTrials.Gov identifier NCT06111235) [Internet]. 2024 [cited 2024 Dec 2]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06111235"},{"key":"e_1_3_5_77_1","doi-asserted-by":"publisher","DOI":"10.1002\/1878-0261.13530"},{"key":"e_1_3_5_78_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.4_suppl.635"},{"key":"e_1_3_5_79_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.euo.2024.09.016"},{"key":"e_1_3_5_80_1","unstructured":"IBCN 2024: using urinary genomic disease burden to assess cretostimogene grenadenorepvec: preliminary analysis from the BOND-003 trial [Internet]. 2024 [cited Oct 30]. Available from: https:\/\/www.urotoday.com\/conference-highlights\/ibcn-2024\/155097-ibcn-2024-using-urinary-genomic-disease-burden-to-assess-cretostimogene-grenadenorepvec-preliminary-analysis-from-the-bond-003-trial.html"}],"container-title":["Expert Opinion on Biological Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14712598.2024.2445674","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,2]],"date-time":"2025-02-02T06:41:28Z","timestamp":1738478488000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14712598.2024.2445674"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,9]]},"references-count":78,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["10.1080\/14712598.2024.2445674"],"URL":"https:\/\/doi.org\/10.1080\/14712598.2024.2445674","relation":{},"ISSN":["1471-2598","1744-7682"],"issn-type":[{"value":"1471-2598","type":"print"},{"value":"1744-7682","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,9]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iebt20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iebt20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2024-10-31","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-12-18","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-01-09","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}